GRPH - Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integration to treat or cure serious diseases, announced today that Josh Lehrer, M.D., M.Phil., chief executive officer of Graphite Bio, and Matthew Porteus, M.D., Ph.D., one of the company’s academic founders, will be featured speakers on the “CRISPR and Beyond: Advancing Gene Editing Techniques” panel at the H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference on Wednesday, March 30, 2022, at 4 p.m. ET.
The panel discussion will be webcast live from Graphite Bio’s website at www.graphitebio.com in the Investors section. A replay of the webcast will be archived and available following the event.
About Graphite Bio
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
Learn more about Graphite Bio by visiting www.graphitebio.com and following the company on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005177/en/
Company Contact:
Stephanie Yao
VP, Communications and Investor Relations
443-739-1423
syao@graphitebio.com
Investors:
Stephanie Ascher
Stern IR, Inc.
212-362-1200
ir@graphitebio.com
Media:
Sheryl Seapy
Real Chemistry
949-903-4750
media@graphitebio.com